Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Cell-free DNA methylation profiling may predict cancer risk up to 9 years before diagnosis, new research suggests. Analyzing plasma samples from over 490 participants, scientists found strong signals for prostate and breast cancer — with prostate cancer showing a hazard ratio of 3.55 in high-risk individuals. While not yet clinic-ready, the technology could one day personalize cancer screening and open doors to earlier prevention.
A blood-based test analyzing cell-free DNA (cfDNA) methylation patterns could identify individuals at elevated cancer risk years before they ever receive a diagnosis, according to a new study published in Cell Genomics. Researchers from the University of Toronto examined plasma samples from 491 participants in the Ontario Health Study, some of whom went on to develop prostate or breast cancer up to 9 years after enrollment. The findings suggest that subtle biological signals — including changes linked to immune cells and inflammatory pathways — may be detectable long before a tumor is clinically apparent.
The technology isn't ready for the clinic just yet. Independent validation in larger cohorts, proof that it adds value beyond existing tools like PSA testing and mammography, and cost-effective assay development are all still needed. But experts say it addresses a real gap, particularly for prostate cancer, which currently lacks routine population screening.
By the Numbers:
Why it matters: If validated, cfDNA methylation profiling could transform cancer screening from a one-size-fits-all approach to a personalized, risk-stratified model — catching cancers earlier when they're most treatable, and potentially enabling preventive interventions before disease even develops.
